Marina Biotech aims to sell up to $25 million of units in public sale

Deal funds working capital, capital expenditures, corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 14 – Marina Biotech, Inc. will price a public offering of units of common shares and warrants, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $25 million of units.

Roth Capital Partners and Ladenburg Thalmann are the bookrunning managers.

Proceeds will be used for working capital needs, capital expenditures and other general corporate purposes.

Marina is a nucleic acid-based drug discovery and development company based in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.